Literature DB >> 29130957

Clinical Disease Patterns in a Regional Swiss Cohort of 34 Pyoderma Gangrenosum Patients.

Antonios G A Kolios1, Alissa Gübeli, Barbara Meier, Julia-Tatjana Maul, Thomas Kündig, Jakob Nilsson, Jürg Hafner, Emmanuella Guenova, Katrin Kerl, Mark Anliker, Werner Kempf, Alexander A Navarini, Lars E French, Antonio Cozzio.   

Abstract

BACKGROUND/AIM: Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis often associated with an underlying disease, and clinical data or larger studies are rare.
METHODS: In this retrospective study, disease characteristics, clinical manifestations, and treatment response were evaluated in a Swiss cohort of PG patients.
RESULTS: In participating centers, 34 cases (21 females) of PG were analyzed based on clinical and histological presentation between 2002 and 2012. The mean age at diagnosis was 61.2 years; 50% of the patients experienced only 1 episode of PG. In 13 cases (out of 20), recurrences occurred during PG therapy; 64.1% showed only 1 lesion simultaneously. The predominant localization was the lower limb (67%). The lesions were disseminated in 26.6%. At the time of diagnosis or recurrence, the mean diameter was 37.6 mm and the mean ulcer size was 10.3 cm2. C-reactive protein (CRP) was elevated in 73.2%; leukocytosis was present in 58.9% and neutrophilia in 50.9%. At least 1 associated comorbidity was present in 85% (the most prominent being cardiovascular disease). The most often used systemic treatments were steroids (68.3%), cyclosporine A (31.7%), dapsone (31.7%), and infliximab (13.3%), and the most often used topicals were tacrolimus 0.1% (48.3%) and corticosteroids (35%). PG healed completely at discharge in 50.8%. The average time to diagnosis was 8 months, and the mean duration to healing was 7.1 months.
CONCLUSION: PG is a difficult-to-diagnose skin disease. Here, markers for inflammation such as CRP, leukocytosis, and neutrophilia were elevated in 50-73% of the PG patients.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  C-reactive protein; Leukocytosis; Neutrophilia; Pyoderma gangrenosum; Systemic inflammation

Mesh:

Substances:

Year:  2017        PMID: 29130957     DOI: 10.1159/000481432

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  4 in total

1.  Pyoderma Gangrenosum: A Retrospective Study of Clinical Charac-teristics, Comorbidities, Response to Treatment and Mortality Related to Prednisone Dose.

Authors:  Louise Schøsler; Karsten Fogh; Rikke Bech
Journal:  Acta Derm Venereol       Date:  2021-04-15       Impact factor: 3.875

2.  Paraneoplastic pyoderma gangrenosum associated with adenocarcinoma of the rectosigmoid junction: a case report.

Authors:  Fousséni Alassani; Panawe Kassang; Efoe-Ga Amouzou; Boyodi Tchangai; Kossi Abossisso Sakiye; Tchin Darré; Bayaki Saka; Komla Attipou
Journal:  J Med Case Rep       Date:  2019-12-07

3.  Pyoderma Gangrenosum in an African American Male Initially Presenting as Sepsis.

Authors:  Carly E Wallace; Amit Sharma
Journal:  Cureus       Date:  2022-01-25

Review 4.  Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.

Authors:  Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese
Journal:  Am J Clin Dermatol       Date:  2022-05-24       Impact factor: 6.233

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.